Group 1 - The core viewpoint of the news is that Beijing Baipusi Biotechnology Co., Ltd. experienced a decline in stock price, with a drop of 5.02% to 58.65 CNY per share, and a total market capitalization of 9.844 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - A fund under Bank of China Securities holds a significant position in Baipusi, with the Bank of China Health Industry Mixed Fund (002938) owning 99,000 shares, representing 4.48% of the fund's net value, making it the seventh-largest holding [2] Group 2 - The Bank of China Health Industry Mixed Fund (002938) has a total asset size of 158 million CNY and has achieved a year-to-date return of 58.86%, ranking 653 out of 8172 in its category [2] - The fund manager, Li Mingwei, has been in charge for 2 years and 215 days, with the best and worst fund returns during his tenure both being 4.82% [3]

Group 1 - The core point of the news is the decline in the stock price of Beijing Baipusi Biotechnology Co., Ltd., which fell by 5.02% to 58.65 CNY per share, with a total market capitalization of 9.844 billion CNY [1] - The company was established on July 22, 2010, and went public on October 18, 2021, focusing on providing key biological reagent products and technical services, with its main revenue sources being recombinant proteins (82.27%), antibodies and other reagents (12.88%), technical services (3.04%), and others (1.80%) [1] - Tianhong Fund has a significant holding in Baipusi, with Tianhong Healthcare A (001558) owning 414,200 shares, representing 5.9% of the fund's net value, making it the seventh-largest holding [2] Group 2 - Tianhong Healthcare A (001558) was established on June 30, 2015, and has a current scale of 251 million CNY, with a year-to-date return of 47.25% and a one-year return of 63.92% [2] - The fund manager, Lü Qiao, has been in position for 265 days, with the fund's total assets amounting to 502 million CNY, achieving a best return of 49.24% and a worst return of 48.82% during his tenure [3]

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively engaged in the development of recombinant proteins and cell immunotherapy, with a focus on various disease targets and biomarkers, benefiting from the depreciation of the RMB and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Overview - The company was established on July 22, 2010, and went public on October 18, 2021, primarily providing recombinant proteins and key biological reagent products and technical services [8]. - The main revenue composition includes 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [8]. Group 2: Financial Performance - For the first half of 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38%, and a net profit attributable to shareholders of 83.8 million yuan, up 47.81% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 3: Market Position and Recognition - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong innovation capabilities and high market share in niche markets [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 4: Recent Developments - The company has developed various high-quality recombinant proteins and is expanding its product offerings in the CAR-T cell therapy field, including specific antibodies and various reagent kits [2]. - The company has initiated product development related to monkeypox virus in response to its spread, launching multiple recombinant proteins, antibodies, and reagent kits to support vaccine and therapeutic drug development [2].

Summary of the Conference Call on China's Healthcare Industry Industry Overview - The conference call focused on the **China Healthcare Industry**, specifically the **life sciences sector** [1][6]. - A strong wave of **innovation drug asset licensing** and a new round of **interest rate cuts** are revitalizing the Chinese life sciences industry after years of consolidation [1]. Key Companies Covered - **Acrobiosystems** (百普赛斯) - Rated **Overweight** with a target price of **RMB 102.50** [11][12]. - **Tofflon** (东富龙) - Rated **Equal-weight** with a target price of **RMB 16.77** [13][15]. Core Insights - The current upcycle in the industry is driven by the **globalization of early-stage innovative drug assets**, leading to increased demand for early drug discovery and development services [2]. - Preference is given to companies that directly serve early drug development needs over those focused on late-stage commercial production, which face challenges such as limited overseas demand and prolonged equipment replacement cycles [2]. - **Acrobiosystems** is considered undervalued due to its unique operational platform, focus on industrial clients, and strong growth potential driven by innovation drug development [2][11]. - **Tofflon** is expected to maintain a reasonable valuation despite moderate terminal market demand and a complex domestic replacement process [13][14]. Financial Metrics - **Acrobiosystems**: - Expected **CAGR** of **55%** from 2024 to 2027, with a current **P/E** ratio of **34x** for 2026 [11][12]. - Anticipated **net profit margin** expansion due to strong sales growth and operational leverage [11]. - **Tofflon**: - Expected **CAGR** of **42%** from 2024 to 2027, with a current **P/E** ratio of **22x** for 2026 [14][15]. - Revenue projections show a gradual increase from **RMB 5.01 billion** in 2024 to **RMB 6.24 billion** in 2027 [15]. Risks Identified - **Downside Risks**: - Geopolitical uncertainties, unexpected regulatory changes, price competition, and delays in domestic replacement processes [3]. - **Upside Potential**: - Accelerated domestic replacement processes, increased demand from a growing drug pipeline, and easing geopolitical concerns could enhance valuations [3]. Conclusion - The Chinese life sciences sector is poised for growth driven by innovation and favorable financing conditions, with specific companies like **Acrobiosystems** and **Tofflon** positioned to capitalize on these trends. The analysis suggests a favorable investment environment, albeit with certain risks that need to be monitored closely [1][2][3].

证券日报网讯 9月16日晚间，百普赛斯发布公告称，公司于2025年9月16日召开职工代表大会，通过民 主选举，选举屈文婷女士为公司第二届董事会职工代表董事。 （文章来源：证券日报） ...

Group 1 - The company Baipusais (SZ 301080) announced the convening of its 20th meeting of the second board of directors on September 16, 2025, in Beijing, where it reviewed the proposal for the re-election of members of the strategic committee [1] - For the fiscal year 2024, Baipusais reported that 98.13% of its revenue came from research and experimental development, while other businesses accounted for 1.87% [1] - As of the report date, Baipusais has a market capitalization of 10.3 billion yuan [1]

北京百普赛斯生物科技股份有限公司 证券代码：301080 证券简称：百普赛斯 公告编号：2025-063 关于公司董事离任暨选举职工董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事离任情况 1、离任基本情况 北京百普赛斯生物科技股份有限公司（以下简称"公司"）于 2025 年 9 月 16 日收到公司非独立董事黄旭女士递交的书面辞职报告。因公司内部工作调整，黄 旭女士申请辞去公司第二届董事会非独立董事职务，同时一并辞去第二届董事会 战略委员会委员职务。黄旭女士辞职后将继续在公司担任副总经理。黄旭女士原 任期届满之日为 2026 年 8 月 1 日。 截至本公告披露日，黄旭女士通过安义百普嘉乐企业管理咨询合伙企业（有 限合伙）间接持有公司股票 370,588 股，不存在应履行而未履行的承诺事项。 黄旭女士所持股份将继续遵守《上市公司董事和高级管理人员所持本公司股 份及其变动管理规则》《深圳证券交易所上市公司自律监管指引第 18 号——股 东及董事、高级管理人员减持股份》等法律法规的规定以及其做出的相关承诺。 2、离任对上市公司的影响 黄旭女士 ...

证券代码：301080 证券简称：百普赛斯 公告编号：2025-062 北京百普赛斯生物科技股份有限公司 第二届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京百普赛斯生物科技股份有限公司（以下简称"公司"）第二届董事会第二 十一次会议于 2025 年 9 月 16 日下午 16:00 在北京市北京经济技术开发区宏达北 路 8 号公司会议室以通讯表决和现场表决的方式召开。本次会议通知及会议资料 于 2025 年 9 月 16 日以专人送达、传真、电子邮件的方式发出。本次会议为紧急 会议，根据《公司章程》的有关规定，出席会议的董事同意豁免本次董事会会议 的通知时限要求。会议应出席董事 7 人：参与现场会议的董事 1 人；参与通讯会 议的董事 6 人，分别为苗景赟先生、李杨女士、屈文婷女士、许娟红女士、刘峰 先生、张勇先生。会议由董事长陈宜顶先生主持，公司高级管理人员列席会议。 会议的召集、召开符合法律、法规、规则和《公司章程》规定。 二、董事会会议审议情况 审议通过《关于补选第二届董事会战略委员会委员的议 ...

24BJ7200118/SH/wg/cm/D18 上海市通力律师事务所(以下简称"本所")接受北京百普赛斯生物科技股份有限公司 (以下简称"公司")的委托,指派本所黄雅程律师、许宸律师(以下简称"本所律师")根据 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规 和规范性文件(以下统称"法律法规")及《北京百普赛斯生物科技股份有限公司章程》(以 下简称"公司章程")的规定就公司 2025 年第三次临时股东大会(以下简称"本次股东大 会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见,并 不对本次股东大会所审议的议案内容以及该等议案所表述的事实或数据的真实性 ...

特别提示： 1、本次股东大会无变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、现场会议召开时间：2025 年 9 月 16 日（星期二）下午 14:30 2、网络投票时间： 证券代码：301080 证券简称：百普赛斯 公告编号：2025-061 北京百普赛斯生物科技股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2025 年 9 月 16 日 9:15-15:00 期间的任意时间。 通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00； 3、会议召开地点：北京市北京经济技术开发区宏达北路 8 号北京百普赛斯 生物科技股份有限公司（以下简称"公司"）二层会议室 4、会议的召开方式：现场表决与网络投票相结合的方式 5、会议召集人：公司董事会 6、会议主持人：董事长陈宜顶先生。 7、本次股东大会的召集和召开符合《中 ...